文献速递类风湿关节炎

甲氨蝶呤与类风湿关节炎间质性肺病及呼吸衰竭风险:全国性人群研究

Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

结果显示,MTX治疗与ILD风险无增加相关(HR 1.00,95%CI 0.78-1.27),与呼吸衰竭风险降低相关(HR 0.54,95%CI 0.43-0.67);RA人群ILD的标准化发病比(SIR)较一般人群高3-4倍,但MTX治疗者与整个RA人群相似。

要点

  • MTX治疗与RA患者ILD风险无增加相关(HR 1.00,95%CI 0.78-1.27)。
  • MTX治疗与呼吸衰竭风险降低相关(HR 0.54,95%CI 0.43-0.67)。
  • RA人群ILD风险较一般人群高3-4倍,但MTX未进一步增加风险。

核心结论

  • RA患者较一般人群ILD风险增加,但MTX治疗未进一步增加ILD或呼吸衰竭风险。

主要发现

  • MTX暴露(一次或以上购药 vs 无购药)与ILD风险无增加相关(HR 1.00,95%CI 0.78-1.27),与呼吸衰竭风险降低相关(HR 0.54,95%CI 0.43-0.67),随访5年。
  • MTX治疗的RA患者ILD的SIR较背景人群高3-4倍,但与整个RA人群相似。

临床怎么用

  • RA患者使用MTX时无需因ILD风险担忧而避免用药,但应关注RA患者本身较高的ILD风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: MTX is the most commonly recommended DMARD for first-line treatment of RA, however, it has been hypothesized to cause lung disease as an adverse effect. We investigated the risk of interstitial lung disease (ILD) and acute and chronic respiratory failure in persons with RA treated with MTX and other medications. METHODS: From the Danish National Patient Register (NPR) and the DANBIO register for rheumatic diseases, we retrieved data on 30 512 persons with RA registered in 1997-2015. Information on ILD and respiratory failure was obtained from the NPR. Information on age and sex for all Danish citizens was obtained from the Danish Civil Registration System. MTX and other medication purchases were retrieved from the Danish Prescription Registry. Associations between MTX and lung disease outcomes were analysed in Cox regression models with adjustment for age, calendar time, sex and other medications. Standardized incidence ratios (SIRs) of lung disease were calculated to compare the RA population with the general population. RESULTS: There was no increased risk of lung disease with MTX treatment [one or more purchases compared with no purchases; HR 1.00 (95% CI 0.78, 1.27) for ILD and 0.54 (95% CI 0.43, 0.67) for respiratory failure] at the 5 year follow-up. The SIR was three to four times higher for ILD in MTX-treated persons with RA, but similar to the whole RA population compared with the background population. CONCLUSION: Persons with RA had an increased risk of ILD compared with the general population, but there was no further increased risk associated with MTX treatment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Ibfelt EH, Jacobsen RK, Kopp TI, et al. Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study. Rheumatology (Oxford). 2021. PMID: 32780828. doi:10.1093/rheumatology/keaa327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。